Signet Healthcare Partners

The Fund V team is led by three senior investment professionals: Founding Partner James Gale and Managing Directors Ashley Friedman and Nikhil Puri. They are supported by a network of venture partners and operating advisors, including former senior executives from Pfizer, Teva, and Johnson & Johnson. Investment decisions are made collectively at the partnership level, with board seats taken actively post-close.

No. Signet explicitly does not typically invest in earlier-stage development companies. The firm focuses on commercial-stage healthcare companies that are already generating revenue or are preparing for commercial launch. The business stage overlaps with late-stage venture capital and private equity, targeting companies with existing products and customers rather than those in preclinical or Phase I trials.

Sourcing relies on the team's 25-year network in healthcare, with a dedicated Business Development Officer, Vladimir Walko, who has more than 25 years of experience across pharmaceutical outsourcing and cell and gene therapy services. The firm also works with a network of operating partners and advisors who bring direct industry relationships. Signet leads rounds and builds syndicates when necessary, which contributes to proprietary flow.

Signet's typical investment is $10 million to $50 million per portfolio company. The firm states that larger investments are available via co-investments. It takes significant minority or majority equity positions and prefers to act as a lead investor, building syndicates around its own commitments rather than passively following other sponsors.

The firm invests primarily in North America and Europe but has a history of investing in other geographies, usually with a local partner. Board seats are held across portfolio companies in the US, Canada (e.g., Knight Therapeutics, TSX: GUD), and Europe (e.g., NorthX Biologics AB in Sweden, Curida Group in Norway).

Signet is a pure private equity firm, not a family office. It raises blind-pool funds from external institutional limited partners and has done so across five vintages since 1998. The firm does not manage a single-family balance sheet, and no wealth-origin story is attached to the GP — it was founded by James Gale after his career in investment banking and principal investing at Gruntal & Co.

No separate philanthropic foundation or impact-investing vehicle is publicly disclosed alongside the private equity funds. The firm's sole activity is growth-capital investing through its commingled vehicles. One advisor, Ted Odlaug, serves as President of the Board of the Dravet Syndrome Foundation in a personal capacity.